Find verified Cariprazine API manufacturers, suppliers, and distributors across the globe. Explore companies that offer high-purity Cariprazine for pharmaceutical use, along with product details, certifications, and reliable sourcing options. Compare prices, check availability, and connect directly with trusted suppliers for Cariprazine API.
Alternate Names: Reagila, Cariprazine (RGH-188)
CAS No: 839712-12-8
PubChem CID: 11154555
Mol Formula: C21H32Cl2N4O
Mol Weight: 427.4 g/mol
IUPAC Name: 3-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-1,1-dimethylurea
API Description: Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT1A receptors and as an antagonist at serotonin 5-HT2A receptors. Cariprazine has been investigated in a variety of psychiatric disorders, including schizophrenia, bipolar disorders, and major depressive disorder. Cariprazine gained its first global approval in the US in September 2015 and was later approved by Health Canada in April 2022. It is currently used to treat schizophrenia, and manic or mixed episodes and depressive episodes associated with bipolar I disorder.
